Genfleet Therapeutics (Shanghai) Inc. successfully completed its IPO on the Hong Kong Stock Exchange, raising $234 million. Shares surged approximately 106% above the listing price on the first day of trading, positioning Genfleet strongly in the biotech capital markets. The company focuses on novel therapeutic candidates, and this financing boosts its development pipeline and global visibility. The IPO underscores renewed investor appetite for Chinese biotechs on international exchanges.